GlassScriptPhysician profile
Raymond Weiss
NPI 1598715393
$258,047.58
in general payments reported to CMS, 2019-2025
30 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $29K · 2021: $48K · 2022: $35K · 2023: $30K · 2024: $28K · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Travel and Lodging: $11K · Food and Beverage: $4,780 · Education: $99.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $44,774.80 |
| Travel and Lodging | $10,968.73 |
| Food and Beverage | $4,780.44 |
| Education | $99.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acclarent, INC | $161,016.92 | 2019-2024 | Acclarent Balloon Inflation Device, Trudi Nav Suction, Relieva Spinplus |
| Medical Device Business Services, INC. | $63,804.99 | 2019-2022 | |
| Integra Lifesciences Corporation | $16,546.97 | 2024-2025 | Inspira Air, Acclarent Aera, Integra |
| Smith+Nephew, INC. | $11,500.00 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,076.88 | 2019-2025 | Dupixent |
| Genzyme Corporation | $641.60 | 2019-2025 | |
| Csl Behring | $555.58 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $443.52 | 2021-2025 | Cuvitru, Takhzyro, Eohilia |
| Glaxosmithkline, LLC. | $441.55 | 2019-2024 | Nucala |
| Novartis Pharmaceuticals Corporation | $392.54 | 2019-2025 | |
| Genentech USA, INC. | $188.67 | 2024-2025 | Xolair |
| Optinose US, INC. | $167.86 | 2020-2025 | |
| Arrinex, INC. | $160.31 | 2019 | |
| Amgen INC. | $147.96 | 2022-2023 | Tezspire |
| Grifols USA, LLC | $145.03 | 2020-2024 | Xembify |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $119.68 | 2021-2023 | Rinvoq |
| Biosense Webster, INC. | $104.76 | 2021 | |
| Biocryst US Sales Co., LLC | $100.40 | 2021-2025 | Orladeyo |
| Pfizer INC. | $90.02 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $74.13 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $50.44 | 2021-2023 | |
| Kaleo, INC. | $46.87 | 2021-2022 | |
| Incyte Corporation | $46.09 | 2021-2025 | Opzelura |
| Medtronic, INC. | $36.45 | 2025 | Alar |
| Stryker Corporation | $35.86 | 2019-2021 | |
| Ionis Pharmaceuticals, INC. | $27.38 | 2025 | Dawnzera |
| Adma Biomanufacturing LLC | $24.80 | 2025 | |
| Biocryst Pharmaceuticals, INC. | $24.12 | 2020 | |
| Leo Pharma INC. | $19.97 | 2024 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.